Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Valley Hospital

Neither a doctor nor a teaching hospital

Research payments

$974,424

147 payments

Through program year 2025, Valley Hospital is reported as receiving $974,424 in research payments, across 147 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $66,680 10
2024 Research $27,341 31
2023 Research $17,803 12
2022 Research $554,274 18
2021 Research $56,910 17
2020 Research $155,011 42
2019 Research $96,404 17

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $621,143 13 payments
  2. Boston Scientific Corporation $193,146 70 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $39,413 20 payments
  4. Endotronix, Inc. $33,723 1 payment
  5. Amgen Inc. $29,468 2 payments
  6. Biogen, Inc. $24,060 4 payments
  7. Merck Sharp & Dohme Corporation $23,916 6 payments
  8. AstraZeneca Pharmaceuticals LP $8,876 6 payments
  9. Daiichi Sankyo Inc. $519 24 payments
  10. Medtronic, Inc. $160 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Post-Trial Access Roll-Over Study to Allow Access to Ribociclib (Lee011) for Patients Who Are on Ribociclib Treatment in Novartis-Sponsored Study $432,628 1 payment
  2. A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $75,671 3 payments
  3. Avant Guard $51,610 6 payments
  4. Frozen Af $40,737 7 payments
  5. Observational Registry of Treatment Patterns in US Heart Failure Patients With Reduced Ejection Fraction $39,913 3 payments
  6. Smart CRT $38,190 13 payments
  7. Asap Too $37,838 18 payments
  8. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $36,862 1 payment
  9. Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction $35,413 16 payments
  10. Proactive-Hf $33,723 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record